LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)

Study Overview
=================
Brief Summary
-----------------
This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

Official Title
-----------------
Observational Retrospective Register of Spanish Lung and Melanoma Cancer Patients With COVID19 Disease

Conditions
-----------------
Covid-19, Lung Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed with lung cancer Patients who have contracted COVID-19 infection Exclusion Criteria: Patients diagnosed with lung cancer but no confirmation of COVID-19 infection.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| lung cancer+COVID-19<br>lung cancer patients diagnosed with COVID-19 | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical data of lung cancer patients with COVID-19 diagnoses | Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data. | From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years | 
| Diagnosis data | Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis | From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years | 
| Treatments received | Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as treatments received | From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years | 
| Prognostic factors | Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as prognostic factors. | From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
covid-19, coronavirus, lung cancer